ACPA might also contribute to increased bone loss in the subgroup of ACPA positive SLE patients, but the contribution of ACPA to reduced BMD in the majority of SLE patients is probably limited since the prevalence of ACPA positivity is much lower in patients with SLE compared to patients with rheumatoid arthritis. This evidence concerns the gene PRTN3 and rheumatoid arthritis.